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a  b  s  t  r  a  c  t
We  herein  describe  the  case  of a  70-year-old  female  patient  diagnosed  with  pancreatic  carcinoma.  An
abdominal  enhanced  computed  tomography  scan  revealed  a  poorly  enhanced  mass  (17  mm  ×  15  mm
in  size)  in the  pancreatic  head.  Magnetic  resonance  cholangiopancreatography  revealed  stenosis  of  the
main  pancreatic  and  common  bile  ducts  caused  by a  mass-neighboring  cyst.  Based  on these  ﬁndings,  we
performed  subtotal  stomach-preserving  pancreaticoduodenectomy.  The  patient  demonstrated  a good
postoperative  course,  and  was  discharged  from  our hospital  in remission  49  days  after  the  surgery.  Patho-
logical  ﬁndings  conﬁrmed  that it was  anaplastic  pancreas  carcinoma  (giant  cell  type).  After  the surgery,
we  performed  S-1  adjuvant  chemotherapy  100  mg/day  for four  weeks,  repeated  similarly  every  six weeks
for a total  of  four courses.
We  have  followed  this  case  for over  2  years  so  far with  adjuvant  chemotherapy,  and  no  recurrence
or  metastasis  has been  revealed.  Adjuvant  chemotherapy  with  S-1  in  patients  with  resected  anaplastic
carcinoma  of  the  pancreas  is also  recommended  as a result  of Japan  Adjuvant  Study  Group  of  Pancreatic
Cancer  01(JASPAC-01)  like the  ordinary  pancreatic  ductal  carcinomas.  There  is  a possibility  to achieve
long-term  survival  in  cases  in which  multidisciplinary  treatment  such  as  a curative  resection  and  adjuvant
chemotherapy  are  performed.
©  2016  The  Author(s).  Published  by Elsevier  Ltd on behalf  of  IJS Publishing  Group  Ltd.  This  is  an  open
he CCaccess  article  under  t
. Introduction
Anaplastic carcinoma of the pancreas (APC) is a relatively rare
ype of invasive ductal carcinoma. When APCs are discovered, they
end to invade locally and metastasize to other organs, and are
nown to be associated with poorer prognosis than the ordinary
ancreatic ductal carcinomas [1].
We  herein report a case of APC associated with survival for more
han 24 months after resection with S1 adjuvant chemotherapy.
. Case report
A 70-year-old Japanese woman presented at our hospital with
eneral fatigue that she had been experiencing for 2 weeks. The
atient was admitted to the Gastroenterological Center of our hos-
ital.
∗ Correspondence author at: 2-8-1 Habikino, Habikino-city, Osaka 583-0872,
apan.
E-mail address: nitta@shiroyama-hsp.or.jp (T. Nitta).
ttp://dx.doi.org/10.1016/j.ijscr.2016.04.013
210-2612/© 2016 The Author(s). Published by Elsevier Ltd on behalf of IJS Publishing 
reativecommons.org/licenses/by-nc-nd/4.0/). BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Blood chemistry analyses revealed elevated levels of hepatobil-
iary enzymes without T-bil.
The laboratory ﬁndings on admission were as follows:
AST 143U/l,ALT189U/l,ALP 1146U/l GTP 665U/l. An abdominal
enhanced computed tomography scan revealed a poorly enhanced
mass (17 mm × 15 mm)  in the pancreatic head, which we diagnosed
as pancreatic carcinoma.
Magnetic resonance cholangiopancreatography revealed steno-
sis of the main pancreatic and the common bile ducts caused by a
mass-neighboring cyst (Fig. 1). Based on these ﬁndings, this patient
was diagnosed with pancreatic carcinoma and was  scheduled to
undergo pancreaticoduodenectomy to reduce stenosis of the main
pancreatic tube.
We preformed subtotal stomach-preserving pancreaticoduo-
denectomy following diagnosis of the pancreatic carcinoma.
Histological ﬁnding were Ph,TS2, mixed type, T3, CH(+), DU(−),
S(−), RP(−), PV(−), A(−), PL(−), OO(−), N0, M0.  PCM(−), BCM(−),
DPM(−), D2,R0. This pancreatic carcinoma was  classiﬁed as stage
III by the General Rules for the Study of Pancreatic Cancer (The
6th edition, Revised Version). The patient demonstrated a relatively
good postoperative course, and was discharged from our hospital
in remission 49 days after surgery.
Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 3. Immunohistochemical ﬁndings (staining ×40).
F
Hig. 1. Preoperative magnetic resonance cholangiopancreatography (MRCP).
RCP showed stenosis of the main pancreatic and the common bile ducts caused
y a mass-neighboring cysts(arrow: ←−).
Pathological ﬁndings conﬁrmed that it was anaplastic pancreas
arcinoma (giant cell type; Fig. 2) and these giant cells were positive
or cytokeratin 7 and negative for CD68, suggesting an epithelial
rigin (Fig. 3).
After the surgery, we performed S-1 adjuvant chemotherapy
00 mg/day for four weeks, repeated similarly every six weeks for
 total of four courses, because this cancer was anaplastic pancreas
arcinoma and was classiﬁed as stage III.
We  have observed this case over 2 years so far with adjuvant
hemotherapy and no recurrence or metastasis has been revealed.
. Discussion
APC is an extremely rare type of pancreatic carcinoma that
s characterized by extremely rapid progression and poor out-
omes as compared to ordinary pancreatic ductal carcinomas; [1]
n addition, APC accounts for 2–7% of all pancreatic cancers, and
redominantly occurs in men  [2,3].
APC is considered to have poor prognosis, even after regres-
ion. The 3-year survival rate of patients with APC is less than 3%,
ith a life expectancy of 10–20 months [2,4–6]. A variety of dif-
erent subtypes of APC have been described, including spindle cell,
ig. 2. Histological appearance (hematoxylin-eosin staining, ×40).
istological ﬁndings of the tumor showed multinuclear giant cells (bizarre giant cells) diThe mononuclear and multinuclear cells of the anaplastic carcinoma exhibited
immunoreactivity for cytokeratin 7: CAM5.2 positive.
giant cell, pleomorphic giant cell, and round cell [7]. In Japan, APC
is also classiﬁed into four subtypes according to its microscopic
morphology by the General Rules for the Study of Pancreatic Can-
cer (The 6th Edition,Revised Version): [8] giant cell, osteoclastoid,
pleomorphic and spindle cell types. APC is considered as one of the
pancreatic ductal carcinomas and deﬁned since 2002 (by General
Rules for the Study of Pancreatic Cancer The 5th Edition). How-
ever, we have several classiﬁcations such as those proposed by
the WHO  [9], AFIP [10], and the Japan Pancreas Society. Anaplastic
carcinoma by Japan Pancreas Society is equivalent to undiffer-
entiated carcinomas by WHO  [9], or AFIP [10] (Table 1). On the
other hand, undifferentiated carcinoma by Japan Pancreas Society
is equivalent to medullary carcinoma by WHO  [9], or AFIP [10,11].
Thus, the classiﬁcation of anaplastic carcinoma is much different
between Japan and European countries. We  investigated anaplas-
tic carcinoma by Japan Pancreas Society though Ichushi-Web (Japan
Medical Abstracts Society) from April 2002 to April 2015. Sixty-
three cases were reported as APC, with the following subtypes:
giant cell, 11 cases (17.5%); osteoclastoid, 20 cases (31.7%); pleo-
morphic, 21 cases (33.3%); and spindle cell type, 9 cases (14.3%).
Most were osteoclastoid, and pleomorphic cases (65.0%), but giant
ffusely proliferated: Anaplastic carcinoma of the pancreas (giant cell type).
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Table 1
Classiﬁcation of anaplastic carcinoma of the pancreas.
General Rules for the Study of Pancreatic Cancer [8]
The 6th Edition,Revised Version Japan Pancreas Society
<WHO classiﬁcation> <AFIP classiﬁcation>
Epithelial tumors Epithelial Neoplasms
Malignant Exocrine Neoplasms
Ductal adenocarcinoma Serous neoplasms
Adenosquamous carcinoma Mucinous cystic neoplasms
Colloid carcinoma (mucinous noncystic carcinoma) Intraductal neoplasms
Hepatoid carcinoma Pancreatic intraepithelial neoplasms
Medullary carcinoma Invasive ductal carcinoma
Signet ring cell carcinoma Tubular adenocarcinoma
Undifferentiatedcarcinoma Adenosquamous carcinoma
Undifferentiated carcinoma with osteoclast like giant cells Colloid (mucinous noncystic)adenocarcinoma
Hepatoid carcinoma
Medullary carcinoma
Signet ring cell carcinoma
Undifferentiated carcinoma
Anaplastic sarcomatoid carcinosarcoma
Undifferentiated carcinoma with osteoclast-like giant cell
Acinar cell neoplasms
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Tumors of the Digestive System, Fourth edition. WHO  Press, Geneva.
2010 [9]
ell and spindle cell cases accounted for 20% and giant cell 17.5%
pindle cell 14.3%, respectively.
Over 2-year survival was observed in 14 cases (22.2%); regard-
ng subtypes, these included 7 osteoclastoid, 4 pleomorphic, 2 giant
ell (including our case), and 1 spindle cell. Among APC subtypes,
iant cell and spindle cell type cases had worse prognoses than
ther subtypes. Death within 12 months was observed in 29 cases
46.0%). The subtypes of these cases included 13 pleomorphic, 7
iant cell, 5 spindle cell, and 3 osteoclastoid; cases of osteoclas-
oid subtype seemed to be better tendency of the prognosis than
ther subtypes. Therefore, the prognosis for patients with APC was
uch poorer as reported even if resected. It is necessary to add
he adjuvant-therapy such as chemotherapy or radiation therapy
ot only pancreatic cancer resection in order to improve this prog-
osis. However, according to Neoptolemos et al. [12], adjuvant
hemotherapy confers a signiﬁcant survival beneﬁt in patients with
esected pancreatic cancer, whereas adjuvant chemoradiotherapy
as a deleterious effect on survival. Among possible adjuvant treat-
ents for resectable pancreatic cancer, chemotherapy results in
he best survival outcomes. Adjuvant treatment for resectable pan-
reatic cancer shows a signiﬁcant survival beneﬁt for adjuvant
hemotherapy.
Gemcitabine-based chemotherapy is the famous and standard
djuvant chemotherapy for advanced pancreatic cancer. Among
atients with macroscopic complete removal of pancreatic can-
er, the use of adjuvant gemcitabine for 6 months compared with
bservation alone resulted in increased overall survival as well
s disease-free survival according to the CONKO-001 Randomized
rial [13].
Recently Japan Adjuvant Study Group of Pancreatic Cancer
1(JASPAC-01) [14] phase3 study in patients with stage I–III pan-
reatic cancer compared treatment with S-1 vs. Gemcitabine.
oxicities were comparable in both groups. Rates of disease-free-
urvival at 2 years were 49% vs. 29% (HR = 0.57, 95% CI: 0.45–0.72)
or S-1 vs. Gemcitabine; the corresponding rates of overall sur-
ival at 2 years were 70% vs. 53% (HR = 0.54, 99.8% CI: 0.35–0.83).
 longer follow-up would be needed to ﬁnd out if the disease-free
urvival advantage of S-1 over gemcitabine translates into an over-
ll survival advantage for S-1. S-1 is more effective compared with
emcitabine as the adjuvant chemotherapy. However, it is unfor-
unate that S-1 seems to be considered for only Asian patients with
ancreatic cancer.Hruben R.H., Pitman M.B., Klistra D.S.,: Tumors of Pancreas (AFIP Atlas of
Tumor Pathology Series 4) Armed Force Institute of Pathology. 2007 [10]
S-1 is the key drug as the adjuvant chemotherapy with resected
pancreatic cancer in any rate.
Adjuvant chemotherapy with S-1 in patients with resected APC
is also recommended as a result of JASPAC-01 [14] like the ordinary
pancreatic ductal carcinomas.
Actually, APC without osteoclastoid type seemed to be much
poorer prognosis than other subtypes. We  always administer
adjuvant chemotherapy after resection of pancreatic cancer, par-
ticularly for pleomorphic, giant cell, and spindle cell subtypes.
However, we should select and add another therapy such as
chemotherapy in proportion to histological types of the pancreatic
ductal carcinomas. It might result in a better prognosis to perform
further S-1 based chemotherapy or postoperative chemoradiation
strategies undergoing curative-intent resection of pancreatic can-
cer. We  hope to further evaluate the randomized trial such as
JASPAC-01 [14] in the future. There is a possibility to achieve long-
term survival in cases in which multidisciplinary treatment such as
a curative resection and adjuvant chemotherapy are performed.
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